Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks

From failed psychedelics to unproven AI kiosks: MindBio bets its survival on voice analytics, but cash burn and dilution loom.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 07:00 MBIO · 0.57 MindBio Therapeutics Corp.
Executive Summary
  • MindBio Therapeutics has completed the manufacture and delivery of its first prototype Edge AI Intoxication and Fatigue Detection Kiosks.
  • The hardware integrates proprietary AI-driven voice analysis software (Intox AI) designed to detect intoxication and fatigue from substances like alcohol, cannabis, cocaine, and psychedelics.
  • The solution targets high-risk, regulated industries including mining, aviation, construction, heavy transport, and law enforcement.
  • The company will now transition into rigorous testing, model validation, and data analysis phases in partnership with industry experts and software engineers.
  • The underlying AI prediction model is trained on over 50 million data points.
  • This follows the official launch of the Intox AI software in early June 2026 and aligns with the company's stated roadmap for Q2 2026 prototype delivery.
Material Impact
  • This is a product development milestone, not a commercial or financial event. Prototype delivery does not equate to revenue, validated performance, or customer contracts.
  • The news confirms the company is executing on its hardware roadmap, but validation results and commercial traction remain unproven.
  • Given the stock's recent downtrend from ~$1.25 in April to ~$0.57 in early June, the market has not reacted positively to incremental development updates. The news is expected and incremental.
  • No immediate impact on the company's dire liquidity position or its going concern status.
MBIO · Price
Company Overview
  • MindBio Therapeutics is a pre-revenue health-tech and AI diagnostics company.
  • Originally focused on psychedelic drug development (MB22001 for Major Depressive Disorder), the company pivoted after its Phase 2B trial failed to show efficacy.
  • The current core initiative is an AI-driven voice analytics platform (Intox AI) that detects intoxication and fatigue from speech patterns.
  • The commercial strategy targets high-volume, safety-critical industries (mining, aviation, construction, law enforcement) with a dual-channel approach: a consumer app (Booze AI) and enterprise-grade Edge AI kiosks.
  • The company claims 15 world-first patent applications and positions itself as a first-mover in non-invasive, AI-powered workplace safety diagnostics.
Read the original news release →

More from MindBio Therapeutics Corp.

Jun 04, 2026 · 11:12

MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

Other May 15, 2026 · 08:30

MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

Other May 14, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

Other May 13, 2026 · 08:30

MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

Other May 11, 2026 · 08:45

MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

Other May 11, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Safety Tech Amidst Cash Burn Concerns

Other